Category comparison

triGLP is not a prescription GLP-1 medicine.

The names overlap because ORYGN discusses metabolic signalling pathways. The product categories, evidence requirements, oversight and appropriate uses are different.

Reviewed 3 August 2026 ยท Educational information, not medical advice

At a glance

QuestionORYGN triGLPPrescription GLP-1 medicines
Product categoryDietary supplement containing salmon-derived bioactive peptides.Prescription medicines with approved active pharmaceutical ingredients and specific indications.
FormatORYGN markets triGLP as sublingual drops.Depending on the medicine, products may be injections or oral medicines used under prescribing instructions.
How it is describedORYGN describes support for GLP-1, GLP-2 and GIP signalling pathways.Approved medicines act through defined pharmacological mechanisms described in their prescribing information.
Evidence standardIngredient and supplement evidence must be read for the exact ingredient, dose, population and formulation studied.Approval for a specific use requires drug-development evidence reviewed by the relevant medicines regulator.
Medical supervisionA supplement does not replace diagnosis, prescribing or monitoring.Use requires an authorised prescriber and attention to indications, contraindications, interactions and adverse effects.
Interchangeable?No. triGLP should not be described as a generic, natural version of, or substitute for a prescribed GLP-1 medicine.

Why the shared language causes confusion

GLP-1 and GIP are names used in human metabolic biology. A supplement company may discuss research concerning those pathways, while a prescription product may be a receptor agonist with a defined active drug and approved indication. Mentioning the same pathway does not make two products medically equivalent.

Practical rule: compare evidence, dose, formulation and regulatory category - not just pathway names.

What prescription approval means

For example, the US Food and Drug Administration describes approved medicines such as tirzepatide and semaglutide by their active ingredients, indications, studied dosage schedules and clinical-trial evidence. Approved prescribing information also includes warnings and monitoring requirements.

Dietary supplements follow a different framework. The NIH Office of Dietary Supplements explains that supplements are not approved for effectiveness before marketing in the same way as prescription drugs.

When to speak with a healthcare professional

  • You use diabetes, blood-pressure, anticoagulant or weight-management medication.
  • You are considering changing or stopping a prescribed treatment.
  • You are pregnant, breastfeeding, under 18, managing a medical condition or have a fish allergy.
  • You develop a reaction or new symptom after starting any supplement.

Bring the complete product label and your medication list to the discussion.

Sources